Clinical Trials Logo

Clinical Trial Summary

Background and objects: Neuroinflammation is an active process detectable in the earliest stages of the neurodegeneration pathway. On the other hand, significant neuroinflammation, such as reactive astrocytosis, can also be observed after cerebral ischemic injury. [18F]THK5351 can monitor the neuroinflammatory process due to its high affinity to astrogliosis, and [18F]PMPBB3 is the novel tau protein radiotracer without significant off-target binding to MAO-B. The investigators hypothesize that the neuroinflammation after acute stroke may induce the tau protein accumulation. In the current proposal, our aims are to 1) explore the interaction between neuroinflammation and tau protein accumulation in acute stroke patients by applying both the [18F]PMPBB3 and [18F]THK5351 PET images and 2) determine their influence on the longterm stroke outcome and cognitive performance. Method: The prospective project plans to recruit 2 groups of participants: one is patients with first-ever acute stroke (Group A, n=50), and the other is healthy people as the control group (Group B, n=30). Within 3 weeks of stroke, [18F]THK5351 and [18F]PMPBB3 PET will be done for imaging cerebral neuroinflammation and tau protein distribution. Brain MRI for obtaining structural and functional information will be done within 3 weeks and 3 months after stroke. Clinical and cognitive outcome will be evaluated at week 3 and months 3 and 12. In addition, APOE genotyping and carotid ultrasound will be performed as well. By obtaining the neuroimaging information, such as severity of white matter change and infarction, cortical and hippocampal atrophy, and SUVRs of [18F]THK5351 and [18F]PMPBB3 PET, the study will be able to investigate the complex interaction between neuroinflammation and tau protein accumulation after stroke, and also evaluate their influence on structural changes, stroke outcome and cognitive performance. Group comparisons will be performed using the Chi-square test, independent t test, Mann-Whitney U test, and multiple linear regression, where appropriate. Anticipation: In this project, the investigators will be able to identify the distribution patterns of neuroinflammation and tau protein accumulation after actue stroke. Secondly, the investigators expect that the presence of neuroinflammation and tau protein accumulation will interfere with the functional connectivity. Finally, the investigators expect that the extent of neuroinflammation and tau protein is correlated with stroke outcome and post-stroke cognitive impairment.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04318626
Study type Interventional
Source Chang Gung Memorial Hospital
Contact Huang Kuo-Lun, M.D.
Phone +886-3-3281200
Email drkuolun@cgmh.org.tw
Status Recruiting
Phase Phase 2
Start date November 1, 2020
Completion date July 31, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT06432023 - Imaging - Clinical Evaluation of Altered Nervous System Drainage
Completed NCT03100136 - Test Re-Test Reliability of [11C]PF-06809247 as a Novel PET Tacer Phase 1
Not yet recruiting NCT05129514 - Imaging Lymphatic/Cerebrospinal Fluid (CSF) Drainage From the Head and Neck in Persons With Traumatic Brain Injury: Demonstration of Feasibility and Evaluation of Manual Therapy to Improve Drainage and Facilitate Cognitive Recovery N/A
Enrolling by invitation NCT05350774 - Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2 Phase 2
Completed NCT03058328 - The White Blood Cell Reactivity Following Surgical Trauma and Associated Regulatory Mechanisms.
Withdrawn NCT04423471 - Neuroinflammation, Affective and Cognitive Symptoms in Major Depression and Psoriasis
Recruiting NCT04814355 - The Effect of Celecoxib on Neuroinflammation in MDD Phase 4
Recruiting NCT06391866 - Neuroinflammation/Oxidative Stress/Cardiac Surgery